MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2025018898

Медицинская библиотека · Blood advances · 2026

Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1/2 study.

Holtzman Noa G, Im Annie, Curtis Lauren, Schulz Eduard, Sharma Rubina, Pirsl Filip, Berman Arlene, Ostojic Alen, Magone de Quadros Costa M Teresa, Cowen Edward W, Mays Jacqueline, Comis Leora E, Joe Galen, Peer Cody, Figg William, Rose Jeremy, El Jurdi Najla, Pouzolles Marie, Hakim Frances, Taylor Naomi, Pavletic Steven Z

СтатьяКлиническое исследование II фазыКлиническое исследование I фазыПеревод в очереди

Аннотация

Refractory chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation remains a leading cause of late morbidity and mortality among transplant survivors. Therapeutic targeting of the Janus kinase (JAK)-STAT pathway has proved to be an effective approach for cGVHD; however, toxicities and short response durability have limited the use of available agents. The safety and efficacy of the JAK 1/2 inhibitor baricitinib were investigated in patients with severe cGVHD refractory to at least 2 lines of therapy. This single-center phase 1/2 study enrolled 24 adult patients who received 2 dose levels (DLs) of baricitinib, 2 and 4 mg daily, in an intrapatient dose escalation study design. No dose-limiting toxicities were observed at either DL. Overall response rate at 6 months was 76.2% (95% confidence interval [CI], 52.8-91.8), with responses observed across all involved organs, including sclerotic skin and pulmonary. Median failure-free survival was 19 months (95% CI, 11-26), with no deaths or malignancy relapse on treatment. Clinically meaningful improvements in patient-reported and functional outcomes were seen in this highly morbid cohort. Immune correlative studies showed that baricitinib induced significant reductions in cytokine-induced signaling (STAT phosphorylation) in both CD4+ and CD8+ T cells and in proinflammatory cytokine secretion. Baricitinib was well tolerated and exhibited a high rate of durable responses in a cohort of patients with severe cGVHD, warranting further evaluation in earlier-line and larger-scale studies. This trial was registered at www.clinicaltrials.gov as NCT02759731.

Для цитирования: Holtzman Noa G, Im Annie, Curtis Lauren, Schulz Eduard, Sharma Rubina, Pirsl Filip, Berman Arlene, Ostojic Alen, Magone de Quadros Costa M Teresa, Cowen Edward W, Mays Jacqueline, Comis Leora E, Joe Galen, Peer Cody, Figg William, Rose Jeremy, El Jurdi Najla, Pouzolles Marie, Hakim Frances, Taylor Naomi, Pavletic Steven Z. Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1/2 study.. Blood advances. 2026. DOI: 10.1182/bloodadvances.2025018898.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.